[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myeloid-malignancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myeloid-malignancy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,42,70,95,122,153,175,200,220,252,272,295,316,338,362,392],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100640438","phase-1-an-investigational-study-of-bg-75202-alone-and-in-combination-with-other-agents-in-patients-with-myeloid-malignancies-100640438",false,"NCT07619287","An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies","A Phase 1a\u002F1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies","Inclusion Criteria:\n\n* Patients must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), inclusive, at the time of signing the Informed consent form (ICF).\n* Patients must have a confirmed diagnosis of myeloid malignancies based on 2016 World Health Organization criteria, and meet the following categories:\n\n  * Relapsed\u002Frefractory; myeloid malignancies after ≥1 prior systemic therapy, per ELN; 2022 criteria; patients with actionable genetic alteration must have previously received targeted therapies unless contraindicated, unavailable\u002Finaccessible, or declined by patient.\n* Patients must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.\n\nExclusion Criteria:\n\n* Prior exposure to KAT6A\u002FB inhibitors\u002Fdegraders.\n* A diagnosis of acute promyelocytic leukemia or BCR-ABL-positive leukemia.\n* Known central nervous system involvement by leukemia\n* Use of antileukemic therapies without sufficient washout period\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":19,"type":20},118,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A\u002FB inhibitor) alone and in combination with other agents in patients with myeloid malignancies.",[26],"Myeloid Malignancy",[28],"KAT6 inhibitor","RECRUITING","2026-06-26",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":33},"2026-06-23",{"date":37,"type":20},"2028-09-30",{"name":39,"class":40},"BeOne Medicines","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100400967","phase-1-study-of-lisaftoclax-apg-2575-single-agent-and-combination-with-therapy-in-patients-relapsedrefractory-aml-100400967","NCT04501120","Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed\u002FRefractory AML","A Phase Ib Study of the Safety, Pharmacokinetic of Lisaftoclax (APG-2575) Single Agent and in Combination With Homoharringtonine or Azacitidine in Patients With Relapsed\u002FRefractory AML","Inclusion Criteria:\n\nSubjects who meet each of the following inclusion criteria are eligible to participate in this study:\n\n1. In accordance with the World Health Organization (WHO) 2016 diagnostic criteria for relapsed or refractory acute myeloid leukemia (AML), Mixed phenotype acute leukemia(MPAL), Chronic myelomonocytic leukemia (CMML), Higher-risk myelodysplastic syndrome (HR-MDS) , Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and naïve AML ineligible for treatment with a standard chemotherapy due to age or comorbidities.\n2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -2 (0 to 3 for participants \\>= 60 to 74 years of age who are evaluated as ineligible for treatment with standard chemotherapy).\n3. Subjects can accept oral administration of Lisaftoclax (APG-2575).\n4. Life expectancy ≥ 3 months.\n5. Adequate renal and liver function.\n6. Males, female patients of childbearing potential (postmenopausal women who must have been menopausal for at least 12 months to be considered infertile) and their partners voluntarily take contraception which the investigator considers effective during treatment and at least three months after the last dose of study drug.\n7. Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any study-specific procedures).\n8. Willingness and ability to comply with study procedures and follow-up examination.\n\nExclusion Criteria:\n\nPatients who meet any of the following exclusion criteria are not to be enrolled in this study:\n\n1. Patients diagnosed with acute promyelocytic leukemia or t(9;22)(q34.1;q11.2); BCR-ABL1 positive AML patients.\n2. The persistent toxicities caused by previous chemotherapy or radiotherapy has not been restored to lower than grade 2 by CTCAE 5.0 (except for alopecia).\n3. Known leukemia infiltration of the central nervous system.\n4. Symptomatic active fungal, bacterial and\u002For viral infections.\n5. Prior history of allogeneic hematopoietic stem cell transplantation or adoptive cell immunotherapy, autologous hematopoietic stem cell transplantation within 12 months.\n6. Within 14 days before the first dose of study drug, received chemotherapy (hydroxyurea is permitted more than 24 hours before the first dose of study drug), radiotherapy, surgery, immunotherapy, targeted therapy, biological therapy or any investigational treatment.\n7. Within 7 days before the first dose of study drug, received a strong and\u002For moderate CYP3A inducer and\u002For Inhibitor.\n8. At the discretion of the investigator, gastrointestinal diseases that affect the absorption of Lisaftoclax (APG-2575).\n9. Any other condition or circumstance, at the discretion of the investigator, that patients would be unsuitable for participation in the study.",{"count":50,"type":20},682,[23,52],"PHASE2","The purpose of this study is to assess the safety, pharmacokinetic profile of Lisaftoclax (APG-2575) single agent and in combination with HHT\u002FAZA in patients with relapsed\u002Frefractory AML and related myeloid malignancies.",[55,26],"Relapsed\u002FRefractory Acute Myeloid Leukaemia",[57,58,26,59],"Acute Myeloid Leukaemia (AML)","Bcl-2 Inhibitor","Lisaftoclax (APG-2575)","2026-04-27",{"date":62,"type":33},"2026-04-29",{"date":64,"type":33},"2020-09-28",{"date":66,"type":20},"2029-09",{"name":68,"class":40},"Ascentage Pharma Group Inc.",12,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100526053","phase-1-decitabine-and-venetoclax-treatment-as-maintenance-therapy-in-patients-post-allograft-stem-cell-transplant-100526053","NCT06129734","Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant","Phase 1B\u002F2A Study of Weekly Decitabine and Venetoclax Treatment as Maintenance Therapy in High-Risk Myeloid Malignancy Patients Post Allograft Stem Cell Transplant","Inclusion Criteria:\n\n* Diagnosis of Acute myeloid leukemia, MDS, MDS\u002FAML with high-risk for post-transplant relapse identified by:\n\n  * Very high or high risk by CIBMTR Disease Risk Index (DRI) and\u002For adverse risk by ICC 2022 criteria and\u002For MDS\u002FAML by ICC 2022 criteria.\n  * Very high or high risk by CIBMTR DRI and\u002For by IPSS-M \\> 0.510-12 and\u002For MDS\u002FAML by ICC 2022 criteria.\n* Bone marrow myeloblasts \\\u003C5% at pre-transplant bone marrow aspirate and biopsy with no circulating blasts.\n* Participants must be planned for or have received alloSCT. Any conditioning regimen intensity or graft source (MRD\u002FMUD\u002FHaplo\u002FUCB) is permitted.\n* Participants must be 18 years of age or older.\n* Total bilirubin \\\u003C 2.0 mg\u002FdL (with the exception of participants with known Gilbert's syndrome, who should have direct bilirubin \\\u003C 2 × ULN).\n* Creatinine clearance (CrCl) \\> 30 ml\u002Fmin.\n* ECOG 0-1 performance status.\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document and complete study related procedures.\n* Participants may enroll prior to or after alloSCT. Participants should enroll no later than post transplant day 40, and the the following post-AlloHSCT inclusion criteria must be met in order to initiate the maintenance study treatment:\n\n  * Successful engraftment defined by absolute neutrophil count (ANC) of ≥500\u002Ful and platelet count of ≥50,000\u002FuL sustained for at least three consecutive days.\n  * These criteria for engraftment should be met on or before Day +50.\n  * No active infection\n  * No GVHD ≥ overall grade II (Grade 1 GVHD of the skin acceptable).\n  * Participants must continue to meet additional inclusion criteria\n  * \\\u003C5% myeloblasts in a bone marrow aspirate with spicules, that is to be obtained, if all the above inclusion criteria are satisfied.\n\nExclusion Criteria:\n\n* Prior disease progression on HMA\u002FVEN therapy, single agent venetoclax.\n* Other planned post-transplant maintenance therapy, such as FLT3-ITD targeting agents, as determined by the treating physician\n* Currently pregnant or breast-feeding. Females of childbearing (FOCBP) potential must have negative serum pregnancy test within 72 hours from treatment start. (NOTE: FOCBP is any biologic female, regardless of sexual or gender orientation, having undergone tubal ligation, or remaining celibate by choice, who has not undergone a documented hysterectomy or bilateral oophorectomy or has had a menses any time in the preceding 12 months (therefore not naturally post-menopausal for \\> 12 months)\n* Uncontrolled comorbid illness that could limit life expectancy or ability to complete study correlates. This includes, but is not limited to:\n\n  * Active infection\n  * Uncontrolled concurrent malignancy\n  * Congestive heart failure of NYHA class III\u002FIV. Participants with compensated heart failure are permitted.\n  * Unstable angina pectoris\n  * New or unstable cardiac arrhythmia. Stable or controlled arrhythmias are permitted\n  * Decompensated liver cirrhosis (Child-Pugh score ≥12 or a MELD score ≥21\n  * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n  * Any other prior or ongoing condition, in the opinion of the investigator, that could adversely affect the safety of the participants or impair the assessment of study results.\n* FOCBP and males that are unwilling to agree to use dual contraceptive measures (i.e., hormonal or barrier method of birth control; abstinence, condom) prior to study entry and for the duration of study participation. Should a female subject become pregnant or suspect she is pregnant while participating in this study, they should inform the treating physician immediately\n* Sexually active male who is unwilling to use a condom when engaging in any sexual contact with a female with child-bearing potential, beginning at the screening visit and continuing until 4 weeks after taking the last dose of decitabine\u002Fvenetoclax.\n* Participants with known active HIV infection, as this will further increase the risk for opportunistic infections. However, participants with chronic HIV with undetectable viral load by PCR, without opportunistic infection, and on a stable regimen of antiretroviral therapy would be eligible.\n* Known allergy or hypersensitivity to any component of decitabine\u002Fvenetoclax",{"count":78,"type":20},20,[23,52],"The goal of this interventional clinical trial is to determine if low doses of gentle chemotherapy after bone marrow transplant may prevent relapse and promote an increase in survival and decrease in side effects in participants with acute myeloid leukemia and myelodysplastic syndromes. The main question it aims to answer is whether or not providing a new, gentler way of administering chemotherapy will help control leftover cancer with minimal side effects. This treatment involves decitabine and venetoclax. Participants will receive standard post-transplant care. Participants will be administered decitabine once per week with normal transplant follow up visits, and then will take a venetoclax pill about 6 to 8 hours later. Participants will meet their study team at the beginning, midway, and at the end of the trial to receive bone marrow testing. Participants will receive treatment until either one year of therapy, relapse, or recurrent dose limiting toxicity (DLT) despite dose reduction.",[26,82],"Acute Myeloid Leukemia",[84],"Allograft Stem Cell Transplant","2026-04-22",{"date":60,"type":33},{"date":88,"type":33},"2025-07-28",{"date":90,"type":20},"2027-07",{"name":92,"class":93},"Benjamin Tomlinson","OTHER",2,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":41},"100601576","germline-testing-for-predisposition-to-myeloid-malignancies-100601576","NCT07112287","Germline Testing for Predisposition to Myeloid Malignancies","MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies","MyeloGen","Inclusion Criteria:\n\n* Age of 18 years or older\n* Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening.\n* Ability to understand and provide a signed and completed consent document in English.\n\nExclusion Criteria:\n\n* Participants who cannot safely undergo clinically indicated skin biopsy as adjudicated by the study team.\n* Participants who have previously undergone germline genetic testing for predisposition to myeloid malignancies",{"count":104,"type":20},200,[106],"NA","The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.",[26,109,110],"Genetic Predisposition to Disease","Myeloid Hematological Malignancies",[112,109],"Myeloid Malignancies","2026-04-21",{"date":115,"type":33},"2026-04-24",{"date":117,"type":33},"2025-11-10",{"date":119,"type":20},"2033-04-01",{"name":121,"class":93},"Christopher Reilly",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":130,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":139,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":41},"100506547","a-telehealth-advance-care-planning-intervention-100506547","NCT05875805","A Telehealth Advance Care Planning Intervention","A Telehealth Advance Care Planning Intervention for Older Patients With Myeloid Malignancies: A Pilot Randomized Controlled Trial","SICP RCT","Inclusion and Exclusion Criteria for Patients\n\nInclusion criteria:\n\n* Age ≥60 years\n* A diagnosis of AML, MDS, and similar myeloid malignancies (including but not limited to MDS\u002FMPN overlap syndrome, myelofibrosis)\n* Being managed in the outpatient settings\n* Able to provide informed consent\n* English-speaking\n\nExclusion criteria:\n\n\\- None\n\nInclusion and Exclusion Criteria for Caregivers\n\nInclusion criteria:\n\n* Age ≥18 years\n* Selected by patient when asked if there is a \"family member, partner, friend, or caregiver with whom you discuss or who can be helpful in health-related matters\"\n* Able to provide informed consent\n* English-speaking\n\nExclusion criteria:\n\n\\- None\n\nInclusion and Exclusion Criteria for Oncology Providers\n\nInclusion criteria:\n\n\\- Oncologists and\u002For APPs who will be conducting the telehealth-delivered ACP visit\n\nExclusion criteria:\n\n\\- None","60 Years",{"count":132,"type":20},207,[106],"The objective of this project is to conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program on healthcare communication, patient anxiety and distress, as well as completion of advance directives (specifically MOLST and healthcare proxy forms) for older patients with acute myeloid leukemia, myelodysplastic syndrome, and similar myeloid malignancies.",[26,82,136,137,138],"Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasm","Myelofibrosis",[140,141,142,143],"Older adults","Myeloid malignancies","Geriatric hematology","Serious illness conversations","2026-03-29",{"date":146,"type":33},"2026-04-03",{"date":148,"type":33},"2024-05-20",{"date":150,"type":20},"2027-12-31",{"name":152,"class":93},"University of Rochester",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":161,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":41},"100613168","considering-allohct-opportunities-for-patient-reflection-during-decision-making-via-digital-stories-100613168","NCT07263074","Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories","Feasibility and Preliminary Efficacy of a Digital Story Intervention to Facilitate Decision-Making in Patients With Myeloid Cancers Considering Allogeneic Hematopoietic Cell Transplantation","CHORDS","Patients\n\nInclusion criteria:\n\n1. Age \\>21 years old\n2. Diagnosis of myeloid cancer (AML, MDS, myelofibrosis, CML, or MDS\u002FMPN)\n3. Being considered for alloHCT\n4. Able to provide informed consent\n5. Able to speak English. The reason for this is because the digital stories have been created in the English language and their multimedia form cannot easily be translated.\n\nExclusion criteria 1) Patients with psychiatric or cognitive conditions which the hematologist believes prohibits informed consent or compliance with study procedures\n\nCaregivers\n\nInclusion criteria:\n\n1. Age \\>18 years old\n2. Selected by the patient when asked if there is a \"family member, partner, friend or caregiver with whom you discuss or who can be helpful in health-related matters.\"\n3. Caregiver may be paid\u002Fprofessional or informal caregiver\n4. Able to provide informed consent\n5. Able to speak English\n\nExclusion Criteria:\n\n1\\) None\n\nHematologists\n\nInclusion criteria:\n\n1\\) Hematologists of the patients who agree to enroll on the study who are part of Wilmot Cancer Institute.\n\nExclusion criteria\n\n1\\) None","21 Years",{"count":163,"type":20},120,[106],"This is a two-arm pilot randomized trial that assesses the feasibility and preliminary efficacy of a digital story and values clarification intervention (Considering alloHCT: Opportunities for Patient Reflection During Decision-Making via Digital Stories \\[CHORDS\\]) compared to usual care among patients with myeloid cancers considering allogeneic hematopoietic cell transplantation (alloHCT).",[26],"2026-03-27",{"date":169,"type":33},"2026-03-30",{"date":171,"type":33},"2026-01-15",{"date":173,"type":20},"2028-06-30",{"name":152,"class":93},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":21,"phases":184,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":41},"100596368","phase-1-trial-of-novel-anti-leukemia-agents-in-flumel-ric-transplant-for-myeloid-malignancies-100596368","NCT07044544","Trial of Novel Anti-leukemia Agents in Flu\u002FMel RIC Transplant for Myeloid Malignancies","A Phase I Trial to Evaluate the Safety and Efficacy of Addition of Novel Anti-leukemia Agents to Flu\u002FMel RIC Transplant for High-risk Myeloid Malignancies","Inclusion Criteria:\n\n1. Adult male or female, age 18-75 years\n2. Patients must have a related or unrelated peripheral blood stem cell donor. Sibling donor must be a 6\u002F6 match for HLA-A and -B at intermediate (or higher) resolution, and -DRB1 at high resolution using DNA-based typing, and must be willing to donate peripheral blood stem cells and meet institutional criteria for donation. Unrelated donor must the following: have Optimum: HLA-A, -B, -C, -DRB1, -DRB3\u002F4\u002F5, -DQA1, -DQB1, -DPA1 and -DPB1; Minimum: HLA-A, -B, -C, -and DRB1 matching at high resolution using DNA-based typing and be willing to donate peripheral blood stem cells and be medically eligible to donate stem cells according to National Marrow Donor Program (NMDP) criteria.\n3. A candidate for reduced intensity preparative regimen, based on age≥60, or HCT-CI of ≥4, or considered by the treating physician to have high risk for toxicity with myeloablative preparative regimen.\n4. Cardiac function: Ejection fraction \\>40%\n5. Calculated creatinine clearance greater than 50 mL\u002Fminute (using the Cockcroft-Gault formula and actual body weight).\n6. Pulmonary function: DLCO ≥50% (adjusted for hemoglobin) and FEV1≥50%\n7. Liver function: total bilirubin \\\u003C 1.5x the upper limit of normal and ALT\u002FAST \\\u003C 2.5x the upper normal limit. Patients who have been diagnosed with Gilbert's Disease are allowed to exceed the defined bilirubin value up to \\\u003C3mg\u002Fdl.\n8. Female subjects (unless postmenopausal for at least 1 year before the screening visit, or surgically sterilized), agree to practice two effective methods of contraception or agree to complete abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post-transplant.\n9. Male subjects (even if surgically sterilized), of partners of women of childbearing potential must agree to practice effective barrier contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post-transplant.\n10. Karnofsky performance status KPS ≥ 70 (Appendix B)\n11. Patients must have a diagnosis of one of the following:\n\n    -AML: A. Any AML with active disease (defined as ≥ 5% blasts in the marrow), with no available re-induction strategies, or further therapy is not felt to be effective by treating physician.\n\n    B. Any AML with adverse risk disease, therapy-related or secondary-AML in CR1 or beyond C. AML with intermediate risk disease that is MRD+ in CR1 or beyond D. Any AML in CR2 or beyond (regardless of MRD) E. Marrow blast percentage needs to be 20-25% and total WBC counts needs to be ≤ 25000\u002Fµl before the start of the conditioning regimen. It is acceptable to use hydroxyurea or low dose cytarabine to maintain this WBC count.\n\n    -MDS:\n\n    MDS with IPSS-M ≥ high and\u002For with ≥5% blasts in the bone marrow with no available pre-transplant strategies, or further therapy is not felt to be effective by treating physician.- MDS\u002FMPN:\n\n    -MDS\u002FMPN \\>5% blasts and spleen \\\u003C 22 cm with no available pre-transplant strategies, or further therapy is not felt to be effective by treating physician.\n12. Subject is willing and able to sign informed consent and abide by the protocol requirements.\n\nExclusion Criteria:\n\n1. Autologous hematopoietic stem cell transplant \\\u003C 3 months prior to enrollment.\n2. Previous allogeneic stem cell transplant.\n3. Uncontrolled angina, severe uncontrolled ventricular arrhythmias, or EKG suggestive of acute ischemia or active conduction system abnormalities.\n4. Known hypersensitivity to Decitabine, Venetoclax and\u002For ATG.)\n5. Pregnant and\u002For breastfeeding\n6. Evidence of HIV infection or known HIV positive serology.\n7. Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings).\n8. Non-hematologic malignancy within prior three (3) years, with the exception of squamous cell or basal cell skin carcinoma. Patients with prior malignancies except resected localized non-melanoma skin cancer or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed as long as it is in remission. Cancer treated with curative intent \\\u003C 5 years previously must be reviewed and approved by the PI as long as it is in remission.\n9. Participation in another clinical study with an investigational product during the last 28 days.\n10. Patients with documented cirrhosis (will need imaging +\u002F- biopsy confirmation, hepatology consult recommended)","75 Years",{"count":78,"type":20},[23],"The purpose of this study is to determine the safety of adding Decitabine and Venetoclax to patients undergoing reduced intensity allogenic transplantation for treatment of hematologic malignances with Fludarabine and Melphalan.",[26,187,82,136],"Hematologic Malignancy",[189,190],"Leukemia","allogeneic transplant","2026-03-02",{"date":193,"type":33},"2026-03-04",{"date":195,"type":33},"2025-07-17",{"date":197,"type":20},"2027-01",{"name":199,"class":93},"University of Alabama at Birmingham",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":182,"enrollmentInfo":206,"targetDuration":4,"studyType":21,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":41},"100351023","phase-2-azacitidine-and-chimerism-in-mds-or-aml-patients-after-allogeneic-stem-cell-transplant-100351023","NCT03850418","Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant","Inclusion Criteria:\n\n1. Patients with AML\u002FMDS\u002FMPN, CMML post Allogeneic SCT who experience any drop in total or myeloid chimerism any time after day 30, or their day 30 or day100 myeloid donor chimerism is below 98% without concurrent hematologic relapse (that is, patients with \\\u003C5% bone marrow blasts as obtained at that time point) will be offered treatment with azacitidine\n2. \\>=30 -180 days post SCT and patients must have ANC\\> 1000, PLT \\> 50,000\n3. Age 18-75 years old\n4. Performance score of at least 70% by Karnofsky\n5. Adequate kidney and liver function as demonstrated by:\n\n   1. Creatinine clearance should be \\>60 ml\u002Fmin\n   2. Total Bilirubin \\\u003C1.5, ALT\u002FAST\u002FAlk Phos \\\u003C 2.5 x normal. No evidence of chronic active hepatitis or cirrhosis.\n6. Negative Beta HCG test in a woman with child bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization. Women of child bearing potential must be willing to use an effective contraceptive measure while on study.\n7. Patient or patient's legal representative, parent(s) or guardian able to sign informed consent.\n8. Patients must be off any prior chemotherapy, radiotherapy, or other investigational therapy within 2 weeks prior to start treatment\n\nExclusion Criteria:\n\n1. Positive for HIV, HBsAg, HCV or other viral hepatitis or cirrhosis from any cause\n2. Active or prior CNS leukemia, unless in complete remission for at least 2 months.\n3. History of serious chronic mental disorder or drug-abuse accompanied by documented problems of compliance with therapeutic programs.\n4. Uncontrolled infection\n5. Grade III, IV graft versus host disease (GVHD",{"count":207,"type":20},43,[52],"Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD",[26],"2026-02-23",{"date":213,"type":33},"2026-02-24",{"date":215,"type":33},"2019-07-01",{"date":217,"type":20},"2028-02-20",{"name":219,"class":93},"Henry Ford Health System",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":21,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":251},"100282586","pre-myeloid-cancer-and-bone-marrow-failure-clinic-study-100282586","NCT02958462","Pre-myeloid Cancer and Bone Marrow Failure Clinic Study","Inclusion Criteria:\n\n* Patients with idiopathic cytopenias of unclear significance (ICUS)\n* Patients with clonal hematopoiesis of indeterminate significance (clonal hematopoiesis of indeterminate potential \\[CHIP\\]), including the recently described CHIP syndrome called VEXAS (vacuoles, E1 ubiquitin ligase, X chromosomal, autoimmune and somatic)\n* Patients with clonal cytopenias of undetermined significance (CCUS)\n* Marrow failure syndromes with myeloid malignancy predisposition - telomere dysfunction, chromosomal breakage disorders\n* Germ line inherited syndromes with risk for malignant transformation - GATA2, CEBPA, ETV-6, RUNX1, JAK2, PF6, etc.\n* Low risk MDS (idiopathic dysplasia of unclear significance)\n* Family member of a patient with one of the above conditions\n* Patient at high risk or suspected of developing one of the above conditions\n\nExclusion Criteria:\n\n* Patients under 18 years of age",{"count":227,"type":20},2000,[106],"This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes. NGS is a procedure that looks at relevant cancer associated genes and what they do. Finding genetic markers for pre-malignant conditions may help identify patients who are at risk of pre-myeloid cancers and bone marrow failure syndromes and lead to earlier intervention.",[26,231,232,233,234,235,236,237,238,239,240,241,242],"Inherited Bone Marrow Failure Syndrome","Clonal Expansion","Cytopenia","Bone Marrow Failure Syndrome","Clonal Cytopenia of Undetermined Significance","Clonal Hematopoiesis of Indeterminate Potential","Hematologic Neoplasms","Hematopoietic and Lymphatic System Neoplasm","Hereditary Neoplastic Syndrome","Idiopathic Cytopenia of Undetermined Significance","Idiopathic Dysplasia of Uncertain Significance","Low Risk Myelodysplastic Syndrome","2026-02-20",{"date":211,"type":33},{"date":246,"type":33},"2017-01-16",{"date":248,"type":20},"2035-09-15",{"name":250,"class":93},"Mayo Clinic",3,{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":21,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":270,"locationsCount":41},"100563826","phase-2-mitoxantrone-hydrochloride-liposome-standard-dose-of-cytarabine-and-venetoclax-in-the-treatment-of-rr-aml-100563826","NCT06621212","Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R\u002FR AML","A Prospective, Multi-center, Phase 2 Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Standard-dose Cytarabine and Venetoclax in the Treatment of Relapsed\u002FRefractory Acute Myeloid Leukemia","Inclusion Criteria:\n\n1. Each subject must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study.\n2. Age ≥18\n3. Clinically diagnosed relapsed\u002Frefractory AML, excluding acute promyelocytic leukemia.\n\n   1. Patients who failed after at least 1 courses of initial induction therapy.\n   2. Bone marrow blasts≥5% after CR\u002FCRi, or reappearance of blasts in the blood in at least 2 peripheral blood samples at least one week apart, or leukemia cell infiltration appeared in extramedullary.\n   3. Conversion from MRD negativity to MRD positivity after CR\u002FCRi.\n4. Physical status score of Eastern Oncology Collaboration Group (ECOG) 0-2.\n5. Life expectancy \\> 3 months.\n6. AST\u002FALT≤2.5 ULN (for subjects with hepatic infiltration≤5 ULN); Total bilirubin≤1.5 ULN (for subjects with hepatic infiltration≤3 ULN); Serum creatinine≤1.5 ULN.\n\nExclusion Criteria:\n\n1. Previous anti-tumor therapy meets one of the following criteria:\n\n   1. Prior therapy with mitoxantrone or mitoxantrone liposome;\n   2. Prior therapy with doxorubicin or anthracyclines, and the cumulative dose of doxorubicin \\> 360 mg\u002Fm\\^2 (1 mg doxorubicin was equivalent to 2 mg daunorubicin or 0.5 mg idarubicin);\n   3. Have received other anti-tumor therapy (including chemotherapy, targeted therapy, hormone therapy, Chinese medicines with anti-tumor activity, except those that do not affect the efficacy of the study as determined by the investigator) or participated in other clinical trials and received clinical trial drugs within 4 weeks or 5 half-lives of the drug before the study;\n2. Subjects who received strong or moderate CYP3A inducers\u002Finhibitors or P-glycoprotein (P-gp) inhibitors within 7 days before starting study treatment;\n3. Subjects who are unable to take oral medications or have malabsorption syndrome;\n4. Cardiovascular diseases, including but not limited to:\n\n   1. QTc interval \\>480 ms or long QTc syndrome in screening;\n   2. Complete left bundle branch block, 2 or 3 grade atrioventricular block;\n   3. Requiring treatment of serious and uncontrolled arrhythmia;\n   4. New York Heart Association NYHA≥2;\n   5. Cardiac ejection fraction (EF) was less than 50%;\n   6. Myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other history of arrhythmia or clinically serious pericardial disease that requires treatment within the first 6 months of enrollment, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities.\n5. Central nervous system leukemia;\n6. Previous or current occurrence of other malignancies (in addition to non-melanoma basal cell carcinoma of the skin that is effectively controlled, breast\u002Fcervical carcinoma in situ, and other malignancies that have been effectively controlled without treatment within the past five years).\n7. Subjects are suffering from any other uncontrollable disease (including but not limited to: uncontrolled diabetes and hypertension, and advanced infection);\n8. HIV infection.\n9. HBsAg or HBcAb positive, with HBV-DNA≥1x10\\^3 copies\u002FmL; or HCV-RNA≥1x10\\^3 copies\u002FmL;\n10. A history of immediate or delayed allergy to similar drug and excipients of the investigate drug.\n11. Pregnant, lactating female or subjects who refuse to use effective contraception during the study.\n12. With a history of severe neurological or psychiatric illness.\n13. Not suitable for this study as decided by the investigator.",{"count":260,"type":20},72,[52],"The purpose of this prospective, multi-center, single-arm, phase 2 study is to evaluate the efficacy and safety of a combination regimen of mitoxantrone hydrochloride liposome injection, standard-dose of cytarabine and venetoclax (MAV) in the treatment of relapsed or refractory (R\u002FR) AML. The study plan to enroll 72 R\u002FR AML patients who are expected to receive laboratory tests of bone marrow and blood specimens at regular times after MAV treatment.",[55,26],"2025-09-10",{"date":266,"type":33},"2025-09-16",{"date":268,"type":33},"2024-07-05",{"date":150,"type":20},{"name":271,"class":93},"First Affiliated Hospital of Zhejiang University",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":21,"phases":281,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":292,"locationsCount":294},"100545172","phase-1-a-study-of-glb-001-in-patients-with-myeloid-malignancies-100545172","NCT06378437","A Study of GLB-001 in Patients With Myeloid Malignancies","A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Myeloid Malignancies","Inclusion Criteria:\n\n* Study participants must understand and voluntarily sign a written informed consent form (ICF) prior to any study-related assessments\u002Fprocedures being performed.\n* Study participants is ≥18 years of age at the time of signing the ICF.\n* Study participants with confirmed diagnosis of relapsed or refractory or intolerant myeloid malignancies including PV, ET, primary myelofibrosis (PMF), MDS and AML according to 2022 World Health Organization (WHO) criteria classification, and post-polycythemia vera myelofibrosis (post-PV MF) and post-essential thrombocythemia myelofibrosis (post-ET MF) according to the 2013 IWG-MRT criteria.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.\n* Life expectancy \\> 3 months.\n* Good performance of major organs, including hematology, liver and kidney function, and coagulation. etc.\n* Study participants are willing and able to adhere to the study visit schedule and other protocol requirements.\n\nExclusion Criteria:\n\n* Study participants with acute promyelocytic leukemia (APL).\n* Receipt of following anticancer medications\u002Ftherapies prior to the first dose of GLB-001: (1) study participants with PV or ET who received treatment with hydroxyurea within 2 days prior to the first dose, or any other treatment for PV or ET within 7 days prior to first dose of GLB-001, (2) study participants with MF who received any type of treatment for MF within 14 days prior to the first dose, such as chemotherapy, immunotherapy, radiotherapy and erythropoietin, androgens, thrombopoietin or granulocyte colony-stimulating factor, (3) study participants with LR-MDS who received any type of treatment for MDS within 14 days prior to the first dose, (4) study participants with HR-MDS or AML who received chimeric antigen receptor T cell therapy (CAR-T) or other biologic therapy within 28 days prior to the first dose of GLB-001, or received any other anticancer therapies within 14 days prior to the first dose of GLB-001.\n* Receipt of any other investigational drug study within 28 days or 5 half-lives of that study drug before the first dose of GLB-001.\n* Study participants with unresolved clinically significant non-hematologic toxicities that were ≥ Grade 1 or failed to recover to baseline levels following prior anticancer therapies (with the exception of alopecia or skin hyperpigmentation).\n* Study participants who are scheduled to receive other anticancer therapies or other investigational drugs during the study period.\n* Study participants with active acute or chronic graft versus host disease (GVHD) requiring systemic immunosuppressive therapy.\n* Receipt of autologous stem cell transplantation (ASCT) within the last 3 months prior to the first dose of GLB-001, or allogeneic hematopoietic stem cell transplantation (allo-HSCT) within the last 6 months prior to the first dose of GLB-001.\n* Study participants with known active involvement in central nervous system (CNS).\n* Study participants with peripheral neuropathy ≥ Grade 2 (Graded according to CTCAE version 5.0).\n* Study participants have a history of known malignancy other than the inclusion diagnosis for the past 5 years, with the exception of curatively resected cancer in situ, including cervical carcinoma in situ, basal cell carcinoma of the skin, or prostate cancer in situ, etc.\n* QT interval interval \\> 450 milliseconds (ms) using electrocardiographic (ECG) at screening.\n* Study participants have impaired cardiac function or clinically significant cardiac disease at current or within last 6 months.\n* Study participants with known active infection of hepatitis B virus (HBV) or hepatitis C virus C (HCV).\n* Study participants with known human immunodeficiency virus (HIV) infection.\n* Study participants with known life-threatening or clinical significant uncontrolled active systemic infections unrelated to malignant hematologic diseases.\n* Study participants with a state condition that may alter affects the absorption, distribution, metabolism and excretion of GLB-001 after judgment of the investigator.\n* Medications or supplements that are known to be strong and moderate inhibitors or inducers of cytochrome P-450 isozyme 3A (CYP3A) and\u002For P-glycoprotein (P-gp), or strong inhibitors or inducers of CYP450 isozyme 2C8 (CYP2C8) within 7 days or 5 half-lives prior to the first dose of GLB-001, whichever is shorter prior to the first dose of GLB-001.\n* Study participants who have undergone major surgery within 28 days prior to the first dose of the GLB-001, or unability to recover from effects of surgery.\n* Pregnant or lactating women.\n* Study participants who have cognitive impairment due to any psychiatric or neurological condition, including epilepsy and dementia, may limit their understanding, performance, and study compliance with the ICF.\n* Study participants, in the opinion of the Investigator, who are unsuitable to participate in the study.",{"count":280,"type":20},108,[23],"Study GLB-001-02 is a phase 1, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 in study participants with relapsed or refractory or intolerant myeloid malignancies including polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), lower-risk myelodysplastic syndrome (LR-MDS), higher-risk myelodysplastic syndromes (HR-MDS), and acute myeloid leukemia (AML). This study consists of 3 parts, dose escalation (Phase 1a), dose exploration (Phase 1b) and dose expansion (Phase 1c). Dose escalation (Phase 1a) and dose exploration (Phase 1b) will evaluate the safety, tolerability, PK, PD and preliminary efficacy of GLB-001, administered orally, in study participants with PV\u002FET, or study participants with MF\u002FLR-MDS\u002FHR-MDS\u002FAML, respectively. Dose expansion (Phase 1c) will be followed to determine the relationships among dose, exposure, toxicity, tolerability and clinical activity, to identify minimally active dose, and to select the recommended dose(s) for phase 2 study. Approximately 108 study participants may be enrolled in the study.",[284,285,138,136,82,26],"Polycythemia Vera","Essential Thrombocythemia","2025-08-17",{"date":288,"type":33},"2025-08-19",{"date":290,"type":33},"2024-05-24",{"date":150,"type":20},{"name":293,"class":40},"Hangzhou GluBio Pharmaceutical Co., Ltd.",14,{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":21,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":41},"100561767","phase-1-hm2023-05-gtb-3650-trike-for-high-risk-mds-and-rr-aml-100561767","NCT06594445","HM2023-05: GTB-3650 Trike for High Risk MDS and R\u002FR AML","HM2023-05: GTB-3650 (Anti-CD16\u002FIL-15\u002FAnti-CD33) Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes (MDS) and Refractory\u002FRelapsed Acute Myeloid Leukemia (AML)","Inclusion Criteria:\n\n* Diagnosis of a high risk myelodysplastic syndromes (MDS), treatment related MDS, OR relapsed\u002Frefractory acute myelogenous leukemia (AML).\n* Absolute lymphocyte count (ALC) ≥ 200 cells\u002FµL OR absolute circulating CD56+\u002FCD3- NK cell count \\>25 cells\u002FµL within the 14 days prior to Cycle 1 Day 1.\n* Peripheral blasts ≤20,000 at the time of treatment start. Hydroxyurea may be used up to Day 1 of the 1st cycle to achieve this threshold and continued for the 1st two weeks of Cycle 1 to maintain it.\n* Karnofsky performance status ≥ 70%\n* Adequate organ function within 14 days (30 days for cardiac) of Cycle 1 Day 1\n* Sexually active persons of childbearing potential or persons with partners of childbearing potential must agree to use a highly effective form of contraception during study treatment and for at least 4 months after the last dose of GTB-3650. Non-childbearing is defined as \\>1 year postmenopausal or surgically sterilized.\n\n-For the Dose Finding Component Only: Must agree to stay within a 60- minute drive of the Study Center through the Cycle 1 Day 29 visit (end of the Dose Limiting Toxicity period).\n\n* Provides voluntary written consent prior to the performance of any research related activity.\n* Pulmonary: room air 0 2 saturation at ≥ 95%\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding. The effect of GTB-3650 TriKE on the fetus is unknown. Persons of childbearing potential must have a negative serum or urine test within 7 days prior to Cycle 1 Day 1 to rule out pregnancy.\n* A candidate for hematopoietic stem cell transplant (HSCT) or newly relapsed after HSCT (e.g. no post-HSCT therapy given).\n* Bi-phenotypic acute leukemia or mixed lineage leukemia.\n* Acute promyelocytic leukemia (APL).\n* No anticancer therapy within 14 days of Cycle 1 Day 1; any AEs from therapy given prior must have resolved to Grade 1 or baseline\n* New or progressive pulmonary infiltrates on screening chest x-ray or chest CT scan unless cleared for study by Pulmonary. Infiltrates attributed to infection must be stable\u002Fimproving with associated clinical improvement after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections).\n* Active systemic infection requiring parenteral antibiotic therapy. Any prior systemic infections must have resolved following optimal therapy.\n* Known history of HIV.\n* Active Hepatitis B or Hepatitis C (virus detectable by PCR) - chronic asymptomatic viral hepatitis is allowed.\n* Positive test results from chronic hepatitis B infection (defined as positive HBsAg serology) and\u002For positive test results for hepatitis C (HCV antibody serology test).\n* Prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer currently in complete remission, or any other cancer from which the patient has been disease-free for 1 year\n* Active central nervous system (CNS) malignancy or symptoms of CNS spread or administration of IT chemotherapy within 14 days prior to Day 1.\n* Extramedullary disease causing symptoms and\u002For involving the CNS or spinal canal - asymptomatic extramedullary disease outside the CNS and spinal canal is eligible provided the marrow has measurable disease.\n* Known autoimmune disease requiring active treatment with steroids or other immunosuppressive medications within 14 days before Cycle 1 Day. Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n* Persons with a condition requiring systemic treatment with steroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days before Cycle 1 Day 1.\n* The potential risk of QT\u002FQTc prolongation is unknown in humans receiving\n\nTriKE therefore either of the following is an exclusion criteria:\n\n* QTc interval \\> 480 msec at screening\n* A family history of long QT syndrome\n* Psychiatric illness\u002Fsocial situations that, in the judgement of the enrolling Investigator, would limit compliance with study requirements.\n* Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient from participating in this study.",{"count":303,"type":20},45,[23],"This is a Phase I dose finding study of GTB-3650 (anti-CD16\u002FIL-15\u002Fanti-CD33) Tri-Specific Killer Engager (TriKE®) for the treatment of select CD33-expressing refractory\u002Frelapsed myeloid malignancies in adults ≥ 18 years of age who are not a candidate for potentially curative therapy, including hematopoietic stem cell transplantation, and are refractory to, intolerant of, or ineligible for therapy options that are known to provide clinical benefit. The hypothesis is GTB-3650 TriKE will induce natural killer (NK) cell function by targeting malignant cells, as well as, CD33+ myeloid derived suppressor cells (MDSC) which contribute to a tumor induced immunosuppression. Because CD16 is the most potent activating receptor on NK cells, this single agent may induce a targeted antiCD33+ tumor response",[26,82,136],"2025-06-27",{"date":309,"type":33},"2025-06-29",{"date":311,"type":33},"2024-11-19",{"date":313,"type":20},"2027-10-30",{"name":315,"class":93},"Masonic Cancer Center, University of Minnesota",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":21,"phases":325,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":337},"100593803","phase-1-a-clinical-trial-of-tqb3909-tablets-in-combination-with-azacitidine-for-the-treatment-of-myeloid-malignancies-100593803","NCT07011186","A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies","A Phase Ib\u002FII Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of TQB3909 Tablets in Combination With Azacitidine in Subjects With Myeloid Malignancies","Inclusion Criteria:\n\n* Voluntary and signed informed consent, good compliance\n* Age: ≥18 years old (at the time of signing the informed consent); expected survival time greater than 3 months.\n* Diagnosis of one of the following diseases:\n\n  1. Acute Myeloid Leukemia (AML):\n  2. Myelodysplastic Syndromes (MDS)\n  3. Major organ functions are normal.\n  4. Fertile male and female subjects agree to use contraception during the study and for 6 months after the study ends.\n\nExclusion Criteria:\n\n* Comorbidities and Medical History:\n\n  1. Diagnosis of or current concomitant malignancy within 3 years prior to the first dose;\n  2. Presence of multiple factors affecting oral drug intake and\u002For absorption;\n  3. Major surgical procedures or significant traumatic injuries within 28 days prior to the first dose;\n  4. History of arterial\u002Fvenous thrombotic events within 6 months prior to the first dose;\n  5. History of psychiatric drug abuse that cannot be discontinued, or psychiatric disorders;\n  6. Presence of any severe and\u002For uncontrolled disease in the subject.\n* Tumor-related Symptoms and Treatment:\n\n  1. Diagnosis of Acute Promyelocytic Leukemia (APL), Myelodysplastic Syndromes\u002FMyeloproliferative Neoplasms (MDS\u002FMPN);\n  2. Presence of leukemia central nervous system (CNS) involvement or high suspicion of CNS involvement but unable to confirm;\n  3. Subjects with extramedullary disease only in AML;\n  4. Presence of life-threatening severe leukemia-related complications;\n* Study Treatment-related:\n\n  1. Received live vaccines within 4 weeks prior to the first dose, or planned to receive live vaccines during the study period;\n  2. Participated in other clinical trials involving anti-tumor drugs within 4 weeks prior to the first dose.",{"count":324,"type":20},138,[23,52],"This is an open, multi-center clinical study designed to evaluate the safety, tolerability and efficacy of TQB3909 tablets in combination with azacitidine in subjects with myeloid malignancies.",[26],"2025-05-30",{"date":330,"type":33},"2025-06-08",{"date":332,"type":33},"2024-04-17",{"date":334,"type":20},"2026-10",{"name":336,"class":40},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",21,{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":345,"enrollmentInfo":346,"targetDuration":4,"studyType":21,"phases":348,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":41},"100503938","phase-2-hypomethylating-agent-and-venetoclax-after-allo-hsct-in-patients-with-high-risk-myeloid-malignancies-100503938","NCT05841771","Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.","A Single Arm, Phase 2 Study Evaluating Safety and Efficacy of Maintenance Therapy With Hypomethylating Agent and Venetoclax After Allogeneic Stem Cell Transplantation in Patients With f High-risk Myeloid Malignancies.","Inclusion Criteria:\n\n* Patients with AML or MDS and have received allogeneic hematopoietic cell transplantation;\n* Patients with AML must have one of the following high-risk factors: Cytogenetics and molecular features consistent with adverse risk group by European LeukemiaNet classification for AML； require more than 2 courses of induction chemotherapy to reach complete remission； Extramedullary myeloid malignancy；≥CR2； Presence of measurable residual disease at the time of HSCT. \\*\n* Patients with MDS must have one of the following high-risk factors: IPSS-R scores are high-risk or very high-risk； Presence of TP53 mutation； Presence of measurable residual disease at the time of HSCT. \\*\n* CBC: ANC ≥ 1.0 × 10e9\u002FL, Hb ≥ 80g\u002FL, and PLT ≥ 50 × 10e9\u002FL；\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n\n  * Presence of measurable residual disease at the time of HSCT is defined as the following: Blast percentage in bone marrow detected by flow cytometry ≥0.01%； Presence of fusion gene or mutated gene by qPCR.\n\nExclusion Criteria:\n\n* Concurrent use of targeted drugs ;\n* Resistant to Venetoclax before transplantation;\n* Allergic to decitabine , Azacitidine or venetoclax;\n* Active grade II or higher acute GVHD ;\n* Active moderate or severe chronic GVHD ;\n* Diseases recurrence (abnormal myeloid cells detected by flow cytometry \\>0.01%, presence of WT1 or other genes, or extramedullary malignancy ), percentage of donor cells in bone marrow \\\u003C90% or graft rejection:\n* CBC: ANC \\\u003C 1.0 × 10e9\u002FL, or PLT \\\u003C 50 × 10e9\u002FL；\n* Severe organ dysfunction: Elevated Aspartate transaminase (AST) \u002Falanine transaminase (ALT), or direct bilirubin \\>3 times upper limit of normal; Creatinine clearance (Ccr)\\\u003C50mL\u002Fmin or serum creatinine \\>1.5 times upper limit of normal, whether hemodialysis treatment is performed;\n* Active uncontrolled systemic fungal, bacterial, or viral infection\n* Pregnant or lactating women;\n* Other severe complications and not suitable judged by researchers.","70 Years",{"count":347,"type":20},78,[52],"The main objective of the study is to evaluate the efficacy and safety of maintenance therapy with hypomethylating agent and Venetoclax to improve leukemia free survival for high-risk myeloid malignancies after allogeneic hematopoietic stem cell transplantation .",[351,352,26],"Hypomethylating Agent","Venetoclax","2024-08-08",{"date":355,"type":33},"2024-08-09",{"date":357,"type":33},"2023-01-01",{"date":359,"type":20},"2025-12-31",{"name":361,"class":93},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":371,"phases":4,"briefSummary":372,"conditions":373,"keywords":376,"overallStatus":382,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":41},"100523045","molecular-services-and-emr-lab-integration-application-elia-for-reducing-healthcare-disparities-in-cancer-patients-100523045","NCT06090513","Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients","Molecular Services and EMR-Laboratory Integration Application (ELIA) for Reducing Leakage and Improving Healthcare Disparities in Cancer Patients","Inclusion Criteria:\n\n* newly diagnosed or change in status Advanced Cancer patient (recurrent, refractory, metastatic, or high grade)\n* Cancer patient for whom genomic testing (comprehensive genomic profile (CGP)) is recommended by relevant guidelines\n\nExclusion Criteria:\n\n* Patient does not seek additional treatment\n* Patient younger than 18 years\n* Treatment provided at a tertiary medical center\n* CGP testing already performed and there is no change in patient cancer status",{"count":370,"type":20},300,"OBSERVATIONAL","The goal of this observational study is to measure and try to reduce leakage in precision medicine care in the community cancer clinic. The goal of precision medicine is to identify the best possible therapy the the patient based on the biology of the tumor. Leakage is defined as a failure or inefficiency of the system that leads to dropped or lost testing, reporting or action (including drug selection). It has been observed that there are healthcare disparities in the community setting compared to academic medical centers, particularly in the use of precision medicine. The main questions the study aims to answer are:\n\n* How much leakage occurs in the use of precision medicine in the community setting?\n* Can we reduce leakage by providing access to better tools and services typically found in the academic medical centers? Participants will not be directly impacted and will receive standard of care. Measurements will be made of how often physicians select the appropriate test for patients, and how often they select the most appropriate therapy for their patients before and after the implementation of tools created to reduce leakage.\n\nWe hope to reduce leakage in with the use of advanced tools and services, and use this study as a model to improve healthcare in the community cancer setting.",[374,375,26],"Advanced Cancer","Solid Tumor, Adult",[377,378,379,380,381],"Comprehensive genomic profile","molecular genetic pathology","community cancer center","healthcare disparities","precision medicine","NOT_YET_RECRUITING","2024-08-05",{"date":385,"type":33},"2024-08-06",{"date":387,"type":20},"2024-10-18",{"date":389,"type":20},"2026-10-18",{"name":391,"class":93},"Bien-Willner Physicians Group PA",{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":21,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":41},"100549487","phase-2-mitoxantrone-hydrochloride-liposome-injection-cytarabine-combined-with-venetoclax-in-the-treatment-of-rr-aml-100549487","NCT06434662","Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R\u002FR AML","A Phase II Study of the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection, Cytarabine and Venetoclax in Patients With Relapsed\u002FRefractory AML","Inclusion Criteria:\n\n1. Each subject must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study.\n2. Age ≥18.\n3. Clinically diagnosed relapsed\u002Frefractory AML, excluding acute promyelocytic leukemia.\n\n   1. Initial treatment patients who failed after 2 courses of treatment with standard regimen.\n   2. Bone marrow blasts≥5% after the first CR\u002FCRi, or reappearance of blasts in the blood in at least 2 peripheral blood samples at least one week apart, or leukemia cell infiltration appeared in extramedullary without treatment.\n   3. First conversion from MRD negativity to MRD positivity without treatment.\n4. Physical status score of Eastern Oncology Collaboration Group (ECOG) : 0-2.\n5. Researchers determined that the patients could tolerate intensive chemotherapy.\n6. Life expectancy \\> 3 months.\n7. AST\u002FALT≤2.5 ULN (for subjects with hepatic infiltration≤5 ULN); Total bilirubin≤1.5 ULN (for subjects with hepatic infiltration≤3 ULN); Serum creatinine≤1.5 ULN.\n\nExclusion Criteria:\n\n1. Previous anti-tumor therapy meets one of the following criteria:\n\n   1. Prior therapy with mitoxantrone or mitoxantrone liposome;\n   2. Prior therapy with doxorubicin or anthracyclines, and the cumulative dose of doxorubicin \\> 360 mg\u002Fm\\^2 (1 mg doxorubicin was equivalent to 2 mg daunorubicin or 0.5 mg idarubicin);\n   3. Have received other anti-tumor therapy (including chemotherapy, targeted therapy, hormone therapy, Chinese medicines with anti-tumor activity, except those that do not affect the efficacy of the study as determined by the investigator) or participated in other clinical trials and received clinical trial drugs within 4 weeks or 5 half-lives of the drug before the study;\n2. Cardiovascular diseases, including but not limited to:\n\n   1. QTc interval \\>480 ms or long QTc syndrome in screening;\n   2. Complete left bundle branch block, 2 or 3 grade atrioventricular block;\n   3. Requiring treatment of serious and uncontrolled arrhythmia;\n   4. New York Heart Association（NYHA≥3;\n   5. Cardiac ejection fraction (EF) was less than 50%;\n   6. Myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other history of arrhythmia or clinically serious pericardial disease that requires treatment within the first 6 months of enrollment, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities.\n3. Central nervous system leukemia;\n4. Previous or current occurrence of other malignancies (in addition to non-melanoma basal cell carcinoma of the skin that is effectively controlled, breast\u002Fcervical carcinoma in situ, and other malignancies that have been effectively controlled without treatment within the past five years).\n5. Subjects are suffering from any other uncontrollable disease (including but not limited to: uncontrolled diabetes and hypertension, and advanced infection);\n6. HIV infection.\n7. HBsAg or HBcAb positive, with HBV-DNA≥1x10\\^3 copies\u002FmL; or HCV-RNA≥1x10\\^3 copies\u002FmL;\n8. A history of immediate or delayed allergy to similar drug and excipients of the investigate drug.\n9. Pregnant, lactating female or subjects who refuse to use effective contraception during the study.\n10. With a history of severe neurological or psychiatric illness.\n11. Not suitable for this study as decided by the investigator.",{"count":400,"type":20},34,[52],"The goal of this study is to evaluate the efficacy and safety of a combination regimen of mitoxantrone hydrochloride liposome injection, cytarabine and venetoclax (MAV) in the treatment of relapsed or refractory (R\u002FR) AML. It will also tentatively explore the correlation between different biological characteristics and therapeutic efficacy. The main questions it aims to answer are:Dose the combination regimen of MAV enhanced the composite complete remission in R\u002FR AML? Participants will receive laboratory tests of bone marrow and blood specimens at regular times after MAV treatment.",[55,26],"2024-05-23",{"date":406,"type":33},"2024-05-30",{"date":408,"type":33},"2024-02-29",{"date":410,"type":20},"2026-06",{"name":271,"class":93}]